{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Veru, Inc. Hits New 52-Week Low at $2.34 Amid Ongoing Challenges
Veru, Inc. has reached a new 52-week low, reflecting ongoing challenges despite a significant one-year performance increase. The company faces financial strain with negative return on equity and a declining operating profit. Its current market cap is USD 57 million, highlighting its microcap status in the Pharmaceuticals & Biotechnology sector.
Veru, Inc. Hits 52-Week Low at $2.42 Amid Market Challenges
Veru, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low, reflecting ongoing market challenges despite a strong one-year performance. The company faces financial difficulties, including negative return on equity and a declining long-term growth outlook, necessitating a strategic reassessment.
Veru, Inc. Stock Hits 52-Week Low at $2.46 Amid Financial Struggles
Veru, Inc. has reached a new 52-week low, reflecting ongoing challenges in the competitive Pharmaceuticals & Biotechnology sector. Despite a strong one-year performance, the company faces significant volatility and financial difficulties, including negative return on equity and a high price-to-book ratio, raising concerns about its long-term growth prospects.
Veru, Inc. Stock Hits 52-Week Low at USD 2.53 Amid Challenges
Veru, Inc., a microcap pharmaceutical company, has reached a new 52-week low, reflecting ongoing challenges in a competitive market despite a strong one-year performance. With a market cap of USD 57 million, the company faces financial difficulties, including negative return on equity and declining operating profit growth.
Is Veru, Inc. technically bullish or bearish?
As of September 8, 2025, Veru, Inc. shows a mildly bullish trend despite bearish indicators in the weekly MACD and moving averages, with a year-to-date return of -45.12% compared to the S&P 500's 12.22%.
Is Veru, Inc. overvalued or undervalued?
As of February 9, 2022, Veru, Inc. is considered overvalued and has a risky valuation grade due to poor financial metrics and significant underperformance compared to the S&P 500, with a year-to-date return of -45.12% and a 3-year return of -97.50%.
Is Veru, Inc. technically bullish or bearish?
As of June 18, 2025, Veru, Inc. shows a mildly bullish trend based on weekly MACD and KST indicators, despite some short-term weakness from daily moving averages and mixed signals from other indicators.
Is Veru, Inc. overvalued or undervalued?
As of February 9, 2022, Veru, Inc. is considered overvalued and has a risky valuation grade due to poor financial ratios, including a Price to Book Value of 4.37 and a ROCE of -2222.48%, alongside weak stock performance compared to its peers and the S&P 500.
Who are in the management team of Veru, Inc.?
As of March 2022, the management team of Veru, Inc. includes Dr. Mitchell Steiner as Chairman, President, and CEO, and Dr. Harry Fisch as Vice Chairman and Chief Corporate Officer, along with independent directors Dr. Mario Eisenberger, Mr. Michael Rankowitz, and Mr. Jesus Socorro.
What does Veru, Inc. do?
Veru, Inc. is a biopharmaceutical company focused on developing treatments for prostate cancer, with a market cap of USD 86.33 million and a recent net profit of -8 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield.
How big is Veru, Inc.?
As of Jun 18, Veru, Inc. has a market capitalization of 86.33 million, with net sales of 10.61 million and a net profit of -29.16 million over the last four quarters. The company reported shareholder's funds of 32.32 million and total assets of 60.81 million as of Sep 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
